2014-14: A Two-Year, Randomized, Double-Masked, Multicenter, Two-Arm Study Comparing the Efficacy and Safety of RTH258 6 mg Versus Aflibercept in Subjects with Neovascular Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is the leading cause of severe vision loss affecting 10-13% of individuals over the age of 65 in western countries. The clinical subtype, neovascular AMD, is characterized by growth of abnormal blood vessels which increases the likelihood of leakage and retinal damage. Without treatment, moste affected eyes will have poor central vision within 12 months. Although anti-vascular endothelial growth factors improve visual outcome, there still remains a need for treatments and regimens which offer a reduced frequency of injections.